Genzyme Reports Strong Second-Quar...(Due to Investment ...)

Common Stock in Equity

NON-GAAP Equivalents Securities

Income Statement Classification:

Total revenues $1,171,134

Cost of products and services sold $(294,019)

Selling, general and administrative $(315,401)

Research and development $(190,769)

Amortization of intangibles $-

Purchase of in-process research

and development $-

Equity in income (loss) of equity

method investments $-

Minority interest $563

Gains (losses) on investments in

equity securities $138 $9,015

Other $19

Investment income $13,352

Interest expense $(1,149)

Summary:

Income (loss) before income taxes $383,868 $- $9,015

(Provision for) benefit from

income taxes $(115,322) $- $(3,283)

Net income (loss) $268,546 $- $5,732

Net income (loss) per share:

Basic $1.01 $- $0.02

Diluted (1) $0.98 $(0.03) $0.02

Weighted average shares outstanding:

Basic 266,904

Diluted (1) 274,576 9,686

License FAS 123R GAAP

Fee Amortization Expense As Reported

Income Statement

Classification:

Total revenues $1,171,134

Cost of products and<
'/>"/>